Despite a rocky start in August, investor sentiment has remained resilient, with the S&P 500 rallying nearly 9% since its August 5th low.
This upward momentum has been driven by a series of positive economic data releases, including better-than-expected initial jobless claims and strong retail sales figures.
Wall Street also reacted favorably to Federal Reserve Chair Jerome Powell’s comments on Friday, signaling that the Fed is prepared to cut interest rates as the labor market softens and inflation approaches the Fed’s 2% annual target.
With this bullish surge in play, the key question is: how can you spot the next hot stock in this environment? One effective strategy is to focus on high-upside stocks endorsed by analysts from top-tier investment banks like Morgan Stanley. These experts bring valuable experience and in-depth knowledge to the table.
In fact, the analysts at Morgan Stanley have highlighted two stocks they believe are poised for significant gains in the coming year – with potential upside as high as 220% in one case. If that’s not enticing enough, according to the TipRanks database, both stocks are also rated as Strong Buys by the analyst consensus. Let’s see what’s driving the unanimous praise from analysts.
COMPASS Pathways (CMPS)
The first Morgan Stanley pick we’ll look at is COMPASS Pathways, a biopharma firm developing innovative treatments for hard-to-treat mental health disorders by leveraging the psychedelic effect of psilocybin. As the active compound in ‘magic mushrooms,’ psilocybin has garnered attention in psychiatric circles for its potential to effectively treat a wide range of mental health conditions.
COMPASS has developed a synthetic psilocybin formulation, known as COMP360, designed to be used in conjunction with psychological support and therapy. The treatment process involves an initial series of sessions where the patient and therapist build rapport, followed by controlled drug administration sessions where the patient receives psilocybin. During these sessions, the patient is closely monitored, and post-session…
..
